In the ED, what is the initial pharmacologic management for a patient with suspected ACS who is not in shock and has no contraindications to antiplatelet therapy?

• A. Start high-dose IV calcium channel blocker and avoid antiplatelets; give oxygen regardless; schedule urgent bypass surgery.
• B. Administer clopidogrel only if aspirin contraindicated; omit nitrates; oxygen should be given to all; await troponin results before any therapy.
• C. Chewable aspirin 160–325 mg; nitrates for chest pain if BP adequate; oxygen only if hypoxemic; obtain serial troponins and activate cath lab if STEMI.
• D. Administer intravenous morphine to relieve pain and observe; oxygen to all patients; begin thrombolytic therapy immediately; ignore troponins.

Answer: (C)

The essential idea is to rapidly initiate antiplatelet therapy and symptom relief while quickly confirming the diagnosis and planning reperfusion if needed. The best initial approach for suspected ACS in a patient who is not in shock and has no antiplatelet contraindications is to give chewable aspirin right away (160–325 mg) to inhibit platelets and reduce mortality. Nitrates are used to relieve chest pain and decrease myocardial oxygen demand, but only if blood pressure is adequate to avoid causing hypotension. Oxygen should be given only if the patient is hypoxemic, since routine oxygen in normoxic patients offers no benefit and can even be harmful in some cases. After starting these therapies, obtain serial troponin measurements to help differentiate NSTEMI from unstable angina and to monitor for evolving myocardial injury. If the ECG shows STEMI, activate the cath lab promptly for reperfusion. This sequence aligns with current ACS practice: immediate aspirin, selective nitrates, restricted oxygen, serial troponins, and rapid reperfusion planning for STEMI.

Why the other approaches aren’t appropriate here: one option would rely on a calcium channel blocker and avoid antiplatelet therapy, which ignores the proven mortality benefit of aspirin in ACS and isn’t a standard initial strategy. Another option delays antiplatelet therapy and nitrates, and suggests waiting for troponin results before starting treatment, which can miss the opportunity to limit infarct size. The last option pushes for morphine and immediate thrombolysis and treats all patients with oxygen, while ignoring troponin results; morphine isn’t first-line for ACS, thrombolytics are reserved for specific STEMI situations, and management should be guided by troponin and ECG findings rather than immediate universal thrombolysis.